Literature DB >> 16728647

Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine.

Michael J Marks1, Paul Whiteaker, Allan C Collins.   

Abstract

Diversity of neuronal nicotinic acetylcholine receptor binding was measured using [3H]epibatidine after deletion of alpha7, beta2, or beta4 subunits. [3H]Epibatidine binding is distinctly biphasic. Densities of higher (Kd approximately 0.02 nM) and lower (Kd approximately 5 nM) affinity sites in whole brains of wild-type mice are very similar. Relative sensitivity to inhibition by cytisine or alpha-bungarotoxin was used to evaluate pharmacological subsets of the higher- and lower-affinity sites, respectively. Deletion of each subunit had distinct effects on the binding sites. Deletion of alpha7 did not affect higher-affinity sites but reduced the numbers of lower-affinity sites. This reduction was confined to the [3H]epibatidine binding sites sensitive to inhibition by alpha-bungarotoxin. Deletion of the beta2 subunit had the largest effect. Higher-affinity sites sensitive to inhibition by cytisine were eliminated, and cytisine-resistant sites were reduced. Deletion of the beta2 subunit also significantly reduced the number of lower-affinity sites insensitive to alpha-bungarotoxin. beta4 Gene deletion partially reduced cytisine-resistant and alpha-bungarotoxin-resistant sites with lower and higher affinity for [3H]epibatidine, respectively. Gene deletion in four brain regions (thalamus, hippocampus, superior colliculus, and inferior colliculus) elicited changes generally similar to whole brain. However, relative expression of the binding sites differed among the regions. [3H]Cytisine and 125I-alpha-bungarotoxin binding sites were eliminated by beta2 and alpha7 gene deletion, respectively. These studies establish that the lower-affinity sites represent a structurally diverse set of sites that require expression of either alpha7, beta2, or beta4 subunits and extend and confirm previous classifications of the higher-affinity [3H]epibatidine binding sites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16728647     DOI: 10.1124/mol.106.025338

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

1.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

2.  Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex.

Authors:  Danielle S Counotte; Natalia A Goriounova; Milena Moretti; Marek T Smoluch; Hubertus Irth; Francesco Clementi; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Cecilia Gotti; Sabine Spijker
Journal:  FASEB J       Date:  2012-02-03       Impact factor: 5.191

3.  The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation.

Authors:  Thomas J Gould; George S Portugal; Jessica M André; Matthew P Tadman; Michael J Marks; Justin W Kenney; Emre Yildirim; Michael Adoff
Journal:  Neuropharmacology       Date:  2012-01-21       Impact factor: 5.250

4.  Decreased α4β2 nicotinic receptor number in the absence of mRNA changes suggests post-transcriptional regulation in the spontaneously hypertensive rat model of ADHD.

Authors:  Mattis B Wigestrand; Yann S Mineur; Christopher J Heath; Frode Fonnum; Marina R Picciotto; Sven Ivar Walaas
Journal:  J Neurochem       Date:  2011-09-01       Impact factor: 5.372

5.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

Review 6.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

7.  Alpha-conotoxin Arenatus IB[V11L,V16D] [corrected] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors.

Authors:  Neal Innocent; Phil D Livingstone; Arik Hone; Atsuko Kimura; Tracey Young; Paul Whiteaker; J Michael McIntosh; Susan Wonnacott
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

8.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

Review 9.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

10.  The alpha 3 subunit gene of the nicotinic acetylcholine receptor is a candidate gene for ethanol stimulation.

Authors:  H M Kamens; C S McKinnon; N Li; M L Helms; J K Belknap; T J Phillips
Journal:  Genes Brain Behav       Date:  2008-09-30       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.